Welcome to our dedicated page for Aytu Biopharma news (Ticker: AYTU), a resource for investors and traders seeking the latest updates and insights on Aytu Biopharma stock.
Aytu BioPharma, Inc. (AYTU) is a Nasdaq-listed pharmaceutical company focused on advancing medicines for complex central nervous system diseases, with an emphasis on major depressive disorder (MDD) and attention deficit-hyperactivity disorder (ADHD). Its news flow reflects this focus, highlighting commercial progress, clinical positioning and corporate developments around its prescription portfolio.
A central theme in Aytu’s recent news is EXXUA (gepirone) extended-release tablets, a novel oral selective serotonin 5HT1a receptor agonist indicated for the treatment of MDD in adults. Company announcements have covered the commercial availability of EXXUA in the United States, its status as the first and only 5HT1a agonist approved by the U.S. Food and Drug Administration for MDD, and integration of EXXUA distribution into Aytu’s RxConnect patient access platform.
Investors following AYTU news will also see updates on the company’s ADHD Portfolio and Pediatric Portfolio performance, including revenue trends and commentary from management in quarterly operational and financial results. Aytu’s press releases discuss net revenue by portfolio, gross profit, adjusted EBITDA and investments related to the EXXUA launch.
In addition, Aytu regularly announces participation in investor conferences, healthcare summits and dedicated Investor Day events. These items often feature presentations by senior management and key opinion leaders in psychiatry, focusing on EXXUA’s clinical profile, market opportunity and the company’s broader CNS strategy. For investors and observers, the AYTU news page provides a centralized view of product launches, patent developments, financing updates and ongoing investor outreach activities.
Aytu BioPharma has secured a global license for AR101 (enzastaurin), targeting vascular Ehlers-Danlos Syndrome (vEDS), a severe genetic disorder lacking FDA-approved treatments. The company paid $1.5 million upfront, with potential milestone payments up to $67.5 million contingent on regulatory and commercial achievements. Two co-founders from Rumpus Therapeutics, Christopher Brooke and Nate Massari, are joining Aytu's executive team to lead the AR101 program. The acquisition aligns with Aytu's strategy to enhance its portfolio in pediatric specialty pharmaceuticals.
Aytu BioPharma (NASDAQ:AYTU) announced the appointment of Richard Eisenstadt as Chief Financial Officer, effective immediately. Eisenstadt brings over 20 years of pharmaceutical finance experience, including capital raising and clinical development. He succeeds David Green, who stepped down on March 31, 2021. Before joining Aytu, Eisenstadt was CFO at Neos Therapeutics, where he raised over $340 million. CEO Josh Disbrow expressed confidence in Eisenstadt’s ability to support the growth of Aytu’s therapeutic portfolio as the company enhances its development pipeline.
Aytu BioPharma (NASDAQ:AYTU) announced a strategic transaction with Acerus Pharmaceuticals, whereby Acerus will acquire all U.S. rights to Natesto. Aytu will receive $7.5M in total, paid in $250,000 monthly installments over 30 months. The deal enables Aytu to focus on pediatric and ADHD therapeutics following their recent merger with Neos Therapeutics. This transition supports Aytu's strategy to enhance shareholder value by concentrating resources on their expanded portfolio of pediatric products.
Aytu BioScience has successfully merged with Neos Therapeutics, becoming Aytu BioPharma. The newly combined company boasts an annual revenue of $100 million, with an anticipated $15 million in cost synergies for 2022. This merger enhances Aytu's position in pediatrics and specialty care markets. Former Neos board members Beth P. Hecht and Gerald McLaughlin join Aytu's board as part of the transition. The merger concluded following approval at shareholder meetings on March 18, 2021, positioning Aytu for future growth and shareholder value enhancement.
Aytu BioScience announced promising results from a pilot study using its Healight technology on mechanically ventilated COVID-19 patients. The study showed that endotracheal ultraviolet A (UVA) light therapy significantly reduced SARS-CoV-2 viral load by over 99% and improved clinical severity scores. Conducted on five patients, the treatment was well tolerated with no serious adverse effects reported. Aytu plans to further collaborate with the FDA and explore additional applications beyond COVID-19.
Aytu BioScience (NASDAQ:AYTU) has announced that CEO Josh Disbrow will present at three investor conferences in March 2021. The events include:
- Cowen 41st Annual Healthcare Conference: March 3, 2021, at 10:20 a.m. ET.
- H.C. Wainwright Global Life Sciences Conference: Pre-recorded chat available March 9, 2021, at 7:00 a.m. ET.
- Oppenheimer 31st Annual Healthcare Conference: March 16, 2021, at 4:30 p.m. ET.
These presentations can be accessed on the Aytu website.
Aytu BioScience announced a definitive merger with Neos Therapeutics, creating a combined specialty pharmaceutical entity with projected revenues of $100 million. For Q2 2021, Aytu reported net revenues of $15.1 million, a significant increase from $13.5 million in Q1 2021, with the Consumer Health division achieving an all-time revenue high of $7.9 million. The Rx division revenue rose 24% sequentially to $7.2 million. Despite a net loss of $9.5 million, Aytu maintains a strong cash position of $62.3 million, indicating financial stability as they approach the merger's closing in Q2 2021.
Aytu BioScience (NASDAQ:AYTU) and Neos Therapeutics (NASDAQ:NEOS) have scheduled special stockholder meetings for March 18, 2021, to discuss their proposed merger. The record date for eligibility to vote is February 5, 2021. Upon closing, the new entity will be rebranded as Aytu Biopharma, Inc., and will retain the AYTU ticker symbol on Nasdaq. Both companies’ Boards recommend stockholders vote 'FOR' the merger proposals. The joint proxy statement/prospectus will be mailed on February 12, 2021, providing further details on the merger process.
Aytu BioScience, Inc. (NASDAQ:AYTU) announced a conference call to discuss its operational results for the fiscal second quarter ending December 31, 2020, scheduled for February 11, 2021, at 4:30 PM ET. During this call, the company will highlight its quarterly accomplishments and future business strategies. Aytu markets several FDA-approved products, including Natesto, ZolpiMist, and Tuzistra XR, along with a range of pediatric medications. Additionally, Aytu is actively involved in COVID-19 testing and has licensed Healight™ technology for potential respiratory treatments.
Aytu BioScience, a specialty pharmaceutical company, announced the completion of a safety study for its Healight™ ultraviolet A light catheter technology. This study focused on critically ill COVID-19 patients on mechanical ventilation in the U.S. The safety data will be presented to the FDA for potential treatment of SARS-CoV-2. CEO Josh Disbrow highlighted this as a significant milestone, aiming for continued FDA discussions. This technology is designed to reduce viral and bacterial loads, with promising pre-clinical findings paving the way for human trials.